Effects of acute and chronic relaxin-3 on food intake and energy expenditure in rats. by McGowan, BM et al.
Effects of acute and chronic relaxin-3 on food intake and energy 
expenditure in rats 
 
 
B.M.C. McGOWAN, S.A. STANLEY, K.L. SMITH, J.S. MINNION, J. DONOVAN 
E.L. THOMPSON, M. PATTERSON, M.M. CONNOLLY, C.R. ABBOTT, C.J. 
SMALL, J.V. GARDINER, M.A. GHATEI & S.R. BLOOM.  
 
Department of Metabolic Medicine, Faculty of Medicine, Imperial College, 6th Floor 
Commonwealth Building, Hammersmith Hospital, Du Cane Road, London W12 
ONN, UK.  
 
Address for correspondence and reprint requests: Stephen Bloom, Department of 
Metabolic Medicine, Imperial College, Hammersmith Campus, 6th Floor 
Commonwealth Building, Du Cane Road, London W12 0NN, UK.  
Tel: 0044 208 383 3242 Fax: 0044 208 383 3142   
E-mail: s.bloom@imperial.ac.uk
 1
 Abstract 
 
The effects of acute and repeated intraparaventricular (iPVN) administration of 
human relaxin-3 (H3) were examined on food intake, energy expenditure, and the 
hypothalamic-pituitary thyroid axis in male Wistar rats.  An acute high dose iPVN 
injection of H3 significantly increased food intake 1 hour post-administration [0.4 ± 
0.1g (vehicle) vs 1.6 ± 0.5g (180pmol H3), 2.4 ± 0.5g (540pmol H3) and 2.2 ± 0.5g 
(1620pmol H3), p< 0.05 for all doses vs vehicle].  Repeated iPVN H3 injection 
(180pmol/twice a day for 7 days) significantly increased cumulative food intake in ad 
libitum fed animals compared with vehicle [211.8 ± 7.1g (vehicle) vs 261.6 ± 6.7g (ad 
libitum fed H3), p< 0.05].  Plasma leptin was increased in the H3 ad libitum fed 
group.  Plasma thyroid stimulating hormone was significantly decreased after acute 
and repeated administration of H3.  These data suggest H3 may play a role in long-
term control of food intake. 
 
Key words: relaxin-3, GPCR135 receptor, appetite, adiposity, energy expenditure 
 
 
 2
 Introduction 
Relaxin-3 (INSL 7) is a recently identified peptide member of the insulin superfamily, 
typified by the presence of an A and B chain linked by inter- and intrachain 
disulphide bonds [1].  Like insulin, the intervening C peptide chain of relaxin-3 is 
removed by proteolytic processing.  The relaxin-3 gene has been identified in humans 
(H3) [2], mice (M3) [2] and rats (R3) [3], and the gene products are highly 
homologous.  R3 and M3 mRNA expression is localized to the nucleus incertus (NI) 
of the brainstem [3], a small nucleus in the central gray of the median dorsal pons 
near the fourth ventricle with projections to many hypothalamic nuclei.  Relaxin-3 
immunoreactive fibers project extensively to hypothalamic areas, including the lateral 
hypothalamic area, the arcuate (ARC) and paraventricular nuclei (PVN) [4; 5]. 
 
Relaxin-3 is the cognate ligand for two previously orphan G-protein-coupled 
receptors, GPCR135 and GPCR142 [6; 7].  GPCR142 is a pseudogene in the rat and 
thus not expressed, but GPCR135 mRNA is highly expressed in the rat brain, 
particularly the PVN and the supraoptic nucleus (SON) [6; 8].  In addition, relaxin-3 
binds to the LGR7 receptor, which also binds relaxin-1 peptide with high affinity and, 
although it is primarily distributed in reproductive tissues, it is also present in the 
CNS [9-11]. 
 
We have recently shown for the first time, that acute intracerebroventricular and 
iPVN administration of low dose H3 stimulates feeding in satiated male Wistar rats in 
the early light phase [12].  The lowest dose of H3 to elicit a significant orexigenic 
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response when administered iPVN was seen in the picomolar range at 18 pmol, 
similar to other orexigenic peptides such as ghrelin and NPY.  
 
The aim of this study was to investigate the maximum acute orexigenic effect of 
iPVN H3 by using higher doses compared to earlier studies, and to establish whether 
acute iPVN administration of H3 may play a role in the regulation of energy 
expenditure and the hypothalamo-pituitary thyroid (HPT) axis.  We also wished to 
examine the effects of chronic (7 days), repeated iPVN administration of H3 on food 
intake, body weight, energy expenditure and the hypothalamo-pituitary axes. 
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Research design and Methods 
Materials 
Human relaxin-3 (H3) was purchased from Phoenix Pharmaceuticals (Belmont, CA) 
and synthesized by the company using solid phase synthesis.  Reagents for 
hypothalamic explant studies were supplied by BDH (Poole, Dorset, UK). 
 
Animal studies 
Male Wistar rats (Specific pathogen free, Charles River, UK) weighing 250-300g 
were maintained in individual cages for all studies except hypothalamic explant 
studies where male Wistar rats, 150-200g, were maintained in cages of five.  All 
animals were kept under controlled temperature (21-23oC) and light (12h light, 12h 
dark, lights on at 0700h) with ad libitum access to food (pelleted RM1 chow diet, 
SDS, UK) and water unless otherwise stated.  All procedures undertaken were 
approved under the British Home Office Animals (Scientific Procedures) Act 1986 
(project license 70/5516).  
 
Intra-paraventricular cannulation and injection 
Male Wistar rats underwent unilateral intra-paraventricular nuclear (iPVN) 
cannulation 7-10 days before feeding studies and were habituated to regular handling 
and injection, as previously described [13].  A 1μl iPVN injection was administered 
over 1 minute via a stainless steel 31-gauge injector, placed in and projecting 1mm 
below the end of the cannula.  Spread of a 1µl injection into the PVN is reported to be 
limited to 1 mm3 [14].  All compounds were dissolved in vehicle (10% acetonitrile in 
0.9% saline) and studies were performed in satiated rats in the early light phase (0900 
– 1000h) unless otherwise stated.  Cannula position was verified histologically at the 
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end of the study [13].  Only those animals with correct cannula placement were 
included in the data analysis. 
  
Study 1 : Acute effects of high dose iPVN relaxin-3 administration on food intake 
Male Wistar rats (n = 10–12) received an iPVN injection of vehicle or increasing 
doses of H3 (180pmol, 540pmol and 1620pmol).  Following injection, animals were 
returned to their home cage with pre-weighed chow.  Food intake was measured at 1, 
2, 4, 8, and 24 hours post-injection.  
 
Study 2: Acute effects of high dose iPVN relaxin-3 administration on plasma TSH  
Male Wistar rats (n = 9-11) received a single injection of vehicle or H3 (540pmol).  
Fifteen or 30 minutes following administration, animals were killed by decapitation 
and plasma was collected into plastic lithium heparin tubes containing 4200 KIU 
aprotinin (Bayer, Haywards Heath, UK).  Plasma was separated by centrifugation, 
frozen and stored at -70˚C until radioimmunoassay (RIA) for thyroid stimulating 
hormone (TSH).  
 
Study 3: Acute effects of iPVN relaxin-3 administration on measurements of energy 
expenditure  
Metabolic parameters were measured following a single iPVN injection of vehicle or 
H3 (180 pmol) (n = 12 per group) in the early light phase (0900 h – 1000 h) by 
indirect calorimetry using an open-circuit Oxymax system of the Comprehensive Lab 
Animal Monitoring System (CLAMS; Columbus instruments, Columbus, OH).  All 
rats were acclimatized to the cages for three days before the injection of vehicle or 
H3.  Animals were maintained at 24°C with a 12:12hr light-dark cycle (light period 
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0700-1900). Food (ground RM1 chow) and water were freely available and food was 
automatically weighed at 30 minute intervals.  Exhaust air from each air tight 
chamber was sampled for one minute at 30 minute intervals. O2 consumption was 
normalised to body weight  to the power of 0.75.  The ambulatory activity of each 
animal was assessed simultaneously using the optical beam technique by an Opto M3 
(Columbus Instruments).   
 
Study 4: Effects of 7 day repeated iPVN administration of relaxin-3 on food intake 
and body weight 
Male Wistar rats were randomized to one of three experimental groups (n= 8-11): 1) 
vehicle – animals received twice daily injections of vehicle (0900h and 1900h) for 7 
days with ad libitum access to food and water, 2) H3 ad libitum fed group – rats 
received twice daily injections of H3 (180pmol) for 7 days with ad libitum access to 
food and water, 3) H3 pair-fed group – rats received twice daily injections of H3 
(180pmol) for 7 days and were pair-fed to the median food intake of the vehicle group 
in the equivalent period 24 hours previously. 
 
Body weight was measured daily at 0900h.  Food was weighed immediately before 
and 1 hour after each injection to allow calculation of cumulative food intake and 
food intake in the first hour in response to each injection.  A final food and body 
weight measurement was taken at 0900h on day 8.  
 
Study 5: Effects of 7 day repeated iPVN administration of relaxin-3 on fat mass, 
plasma hormones and UCP-1 expression  
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Rats from study 4 were killed by decapitation on day 8 at 0900-1000h, and plasma 
was collected as for study 2.  Plasma was assayed for pituitary hormones including 
TSH, prolactin, luteinizing hormone (LH) and growth hormone (GH), as well as 
corticosterone and leptin. Weights of epidydimal fat pads (white adipose tissue or 
WAT), interscapular brown adipose tissue (BAT), adrenals and testes were measured.  
 
Expression of UCP-1 mRNA in interscapular brown adipose tissue was assessed by 
northern blot.  RNA was extracted from BAT using Tri-reagent (Helena Biosciences, 
Sunderland, UK) according to the manufacturer’s protocol.  Northern Blot analysis 
was performed as previously described [15].  The filter was exposed to phosphoscreen 
overnight prior to quantification of UCP-1 mRNA expression using ImageQuant 
software (GE Healthcare, Chalfont St Giles, UK).  Blots were reprobed with 
oligo(dT)12-18 to enable differences in RNA loading to be corrected. 
 
Study 6: Effect of relaxin-3 on in vitro release of hypothalamic neuropeptides 
The static incubation system was used as previously described [16].  After an initial 
2h equilibration period, the hypothalami were incubated for 45 min in 600 μl aCSF 
(basal period) before being challenged with H3 (10 nM) for 45 minutes.  Finally, the 
viability of the tissue was verified by a 45 min exposure to 56mM KCl.  At the end of 
each period, the aCSF was removed and frozen at -20ºC until measurement of 
hypothalamic hormones [Thyrotropin releasing hormone (TRH), Somatotropin release 
inhibitory factor (SRIF)] by RIA. 
 
Radioimmunoassays  
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Plasma pituitary hormone concentrations were assayed using reagents and methods 
provided by the National Institute of Diabetes and Digestive Diseases and the 
National Hormone and Peptide Program (Dr. A. Parlow, Torrance, CA), as previously 
described [16-19].  Hypothalamic hormones (SRIF, TRH) were assayed using in-
house radioimmunoassays (RIAs) as previously described [20; 21].   Leptin (Linco 
Research, Inc, St. Charles, MO), corticosterone (MP Biomedicals, Irvine, CA) and 
free T3 (EuroDPC Ltd, Gwynedd, UK) were measured using commercially available 
RIA kits.  
 
Statistical analysis 
Results are shown as mean ± S.E.M.  Data from acute feeding studies, plasma 
hormone levels and neuropeptide expression were compared by ANOVA with post-
hoc LSD test (Systat, Evanston, IL).  Cumulative food intake and body weight data 
from the repeated injection study was analyzed using marginal models with 
exchangeable correlation matrix and robust standard errors (Stata 8, Statacorp LP, 
TX).  Energy expenditure parameters between control and treated group were 
analyzed using the Mann-Whitney U test (Stata 9, Statacorp, TX, USA).  
Hypothalamic explant data was compared by paired Student t-test between control 
and treated groups.  In all cases, p < 0.05 was considered to be statistically significant.   
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Results 
 
Study 1 : Acute effects of high dose iPVN relaxin-3 administration on food intake 
A single iPVN injection of high dose human relaxin-3 (H3) to satiated male Wistar 
rats significantly increased food intake in the first hour post-administration at all 
doses [0-1 hour food intake: 0.4 ± 0.1 g (vehicle) vs 1.6 ± 0.5 g (180 pmol H3), 2.4 ± 
0.5 g (540 pmol H3), and 2.2 ± 0.5 g (1620 pmol H3), p< 0.05 for all doses vs 
vehicle, n=10-12] (Figure 1).  The effect was also significant at these doses in the 
second hour post-injection [1-2 hour food intake: 0.2 ± 0.1 g (vehicle) vs 2.2 ± 0.7 g 
(180 pmol H3), 2.6 ± 0.4 g (540 pmol H3), and 2.1 ± 0.5 g (1620 pmol H3), p< 0.05 
for all doses vs vehicle].  There was no difference in interval food intake between 
control and treated groups at later time points.  Cumulative food intake was 
significantly increased 2, 4 and 8 hours post iPVN administration of 180, 540 and 
1620 pmol H3 [0-8 hour food intake: 2.7 ± 0.7 g (vehicle) vs 5.6 ± 1.0 g (180 pmol 
H3), 6.3 ± 0.6 g (540 pmol H3), and 6.9 ± 0.6 g (1620 pmol H3), p< 0.05 for all doses 
vs vehicle]. 
 
Study 2: Acute effects of high dose iPVN relaxin-3 administration on thyroid 
stimulating hormone  
IntraPVN administration of H3 (540pmol) significantly reduced plasma thyroid 
stimulating hormone (TSH) at both 15 and 30 minutes following injection compared to 
vehicle [2.46 ± 0.34 ng/ml (vehicle) vs 1.58 ± 0.18 ng/ml (H3) at 15 min, p< 0.05 vs 
vehicle and 3.88 ± 0.44 ng/ml (vehicle) vs 2.48 ± 0.26 ng/ml (H3) at 30 min, p< 0.05 vs 
vehicle, n=9-11] (Figure 2). 
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Study 3: Acute effects of iPVN relaxin-3 administration on measurements of energy 
expenditure  
A single iPVN injection of H3 (180pmol) did not have any effect on VO2 [mean VO2 
consumption for the first 8 hours post-injection: 1006.6 ± 50.3 ml/kg0.75/hr (vehicle) 
vs 1059.2 ± 48.4 ml/kg0.75/hr (H3)].  RER and physical activity did not differ when 
compared to vehicle.  As previously observed, a significant increase in food intake 
was seen in the first hour after H3 administration (data not shown). 
 
Study 4: Effects of 7 day repeated iPVN administration of relaxin-3 on food intake 
and body weight 
At the onset of the study, there was no difference in body weight between the three 
experimental groups (day 1 body weight: 342 ± 9 g, [vehicle] vs 365 ± 7 g, [H3 ad 
libitum fed]  vs 352 ± 10 g [H3 pair-fed]).  Twenty-four hour food intake in the H3 ad 
libitum fed group was significantly higher compared to vehicle at the beginning and 
end of the study [day 1: 22.6 ± 3.0 g (vehicle) vs 33.6 ± 3.6 g (H3), p< 0.05, and day 
7: 32.6 ± 1.0 g (vehicle) vs 38.4 ± 0.9 g (H3), p< 0.05, n=8-11] (Figure 3A).  
IntraPVN injection of 180 pmol H3 stimulated feeding during the first hour following 
injection in both the early light phase and early dark phase on each study day.  There 
was no attenuation in the acute orexigenic response in the early light phase on 
repeated administration up to 7 days [0-1 hour food intake: 0.3 ± 0.2 g (vehicle) and 
2.3 ± 0.6 g (H3) (day 1) vs 0.7 ± 0.3 g (vehicle) and 3.0 ± 0.7 g (H3) (day 7), p< 0.05 
vs vehicle] (Figure 3B).  Trend analysis of cumulative food intake revealed that over 
the period of the study the H3-treated ad libitum fed group ate significantly more than 
vehicle-treated ad libitum fed controls [211.8 ± 7.1 g (vehicle) vs 261.6 ± 6.7 g (H3), 
p< 0.05 vs vehicle at the beginning of day 7] (Figure 4).  There was a trend towards 
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greater cumulative body weight change in the H3-treated ad libitum fed group 
compared to vehicle-treated animals but this did not reach statistical significance on 
day 7 [8 ± 4 g (vehicle) vs 13 ± 4 g (H3)].  There was no difference in cumulative 
body weight change between the H3 pair-fed group compared to vehicle at day 7 [8 ± 
4g (vehicle) vs 2 ± 2 g (H3 pair-fed)], but body weight change was significantly 
reduced in the H3 pair-fed compared to H3-treated ad libitum fed animals [2 ± 2 g 
(H3 pair-fed) vs 13 ± 4g (H3 ad libitum fed), p <0.05]. 
 
Study 5: Effects of 7 day repeated iPVN administration of relaxin-3 on fat mass, 
UCP-1 expression and plasma hormones 
Following an iPVN injection of H3 (180 pmol) or vehicle twice a day for 7 days, 
there was no difference in interscapular BAT weight [0.54 ± 0.03 g (vehicle) vs 0.61 
± 0.04 g (H3 ad libitum fed) vs 0.56 ± 0.04 g (H3 pair-fed)].  There was no difference 
observed in interscapular BAT UCP-1 mRNA expression between the experimental 
groups [12.83 ± 1.80 (vehicle) vs 14.28 ± 2.36 (H3 ad libitum fed) vs 12.42 ± 2.65 
(H3 pair-fed), units are arbitrary] (Table 1).  
 
There was no difference in epididymal fat mass between the 3 groups [3.35 ± 0.27 g 
(vehicle) vs 4.05 ± 0.32 g (H3 ad libitum fed) vs 3.31 ± 0.23 g (H3 pair-fed)].  
However, plasma leptin was significantly elevated in the H3 ad libitum fed group 
compared to vehicle, [2.24 ± 0.40 ng/ml (vehicle) vs 3.67 ± 0.55 ng/ml (H3 ad libitum 
fed) vs 2.05 ± 0.49 (H3 pair-fed), p< 0.05 H3 ad libitum fed vs vehicle, n=8-11] 
(Table 1).  
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A significant suppression of plasma TSH was observed in both the H3 ad libitum fed 
group and H3 pair-fed group when compared to vehicle-treated animals [3.93 ± 0.53 
ng/ml (vehicle) vs 2.44 ± 0.30 ng/ml (H3 ad libitum fed) vs 2.59 ± 0.36 ng/ml (H3 
pair-fed), p< 0.05 H3 ad libitum fed vs vehicle and H3 pair-fed vs vehicle, n=8-11] 
(Figure 5).  There was no difference in plasma free T3 levels between the groups 
[1.24 ± 0.14 pg/ml (vehicle) vs 1.53 ± 0.14 pg/ml (H3 ad libitum fed) vs 1.76 ± 0.22 
pg/ml (H3 pair-fed)].   
 
There were no differences in adrenal and testicular weight between the treatment 
groups and no differences in plasma prolactin, corticosterone, LH and GH plasma 
levels amongst the three groups (data not shown).  
 
Study 6: Effect of relaxin-3 on in vitro release of hypothalamic neuropeptides 
To examine the possible central mediators of the effects of H3 on plasma TSH, 
hypothalamic release of neuropeptides known to regulate thyroid function (TRH and 
SRIF) was determined in response to H3 relaxin in vitro.  TRH was significantly 
reduced by 10nM H3 [50.6 ± 7.2 fmol/explant (basal) vs 39.6 ± 7.1 fmol/explant 
(H3), p< 0.05] whilst SRIF release increased significantly in response to 10nM H3 
[62.0 ± 5.3 fmol/explant (basal) vs 87.5 ± 9.4 fmol/explant (H3), p< 0.05].  
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Discussion 
Little is known of the biological actions of relaxin-3.  We have recently demonstrated 
that relaxin-3 may play a role in the regulation of food intake [12].  The aim of the 
current study was to investigate the maximum orexigenic response elicited by H3.  
Acute iPVN administration of high dose H3 significantly increased food intake in the 
first and second hour post-injection in satiated rats (180-1620 pmol), and 
cumulatively up to 8 hours following injection.  The maximum orexigenic response 
was achieved by a dose of 540 pmol H3 with no further increase at the higher dose of 
1620 pmol H3.  
  
Several peptides, such as NPY and AgRP, which stimulate food intake also alter 
energy expenditure [22-24].  We therefore examined the acute effects of H3 on both 
plasma TSH and other parameters of energy expenditure (VO2, RER and ambulatory 
activity).  Acute iPVN administration of H3 significantly suppressed plasma TSH at 
15 and 30 minutes post injection, suggesting that H3 may play a role in decreasing 
energy expenditure by suppression of the thyroid axis.  However, there were no 
differences  in VO2, RER or physical activity when the effects of acute iPVN 
administration of H3 were examined in the CLAMS system.  It is possible that small 
differences in energy expenditure exist which are below the detection limit of this 
system.  Energy expenditure is comprised of several components: thyroid hormone 
activity, BAT activity, activation of the sympathetic nervous system and both 
locomotor and non-locomotor muscle activity.  Thus, although TSH was suppressed, 
there may be compensation by other components resulting in no overall change in 
energy expenditure in response to H3. 
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Repeated iPVN administration of H3 significantly increased food intake throughout 
the 7 day study.  One hour food intake following injection was significantly increased 
in the first hour following administration in the early light phase on both day 1 and 
day 7 with no evidence of tachyphylaxis.  Repeated 7-day iPVN administration of H3 
significantly increased cumulative food intake in the ad libitum fed, H3 treated 
animals.  However, although cumulative body weight change was increased in this 
group, this failed to reach significance by day 7 of the study.  Plasma leptin was 
significantly elevated in ad libitum fed H3 treated animals and although epididymal 
fat pad weight was higher in the ad libitum fed H3 treated animals this did not achieve 
statistical significance.  This elevation in plasma leptin suggests that whole body 
adipose tissue may be increased and it would be interesting to examine the body 
composition of chronic H3-treated animals in more detail.  However, it is also 
possible that central H3 administration results in a stimulation of leptin secretion.  
Since the efficacy of H3 to increase food intake did not diminish over the course of 
the study, it is possible a significant change in body weight may be achieved by 
administration of higher or more frequent doses of H3, by bilateral injection or with a 
longer study period. 
 
There was no difference in cumulative body weight change between the vehicle 
treated and the H3-treated animals pair-fed to the food intake of the vehicle.  This 
would suggest that there was no significant effect of H3 on energy expenditure and is 
in keeping with the results of acute H3 administration on metabolic parameters. In 
keeping with this, there was no difference in BAT UCP-1 mRNA expression between 
the treatment groups. There was however, a significant difference in cumulative body 
weight change between ad libitum fed H3 treated and H3 pair-fed animals by the end 
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of day 7.  Again, plasma TSH was significantly suppressed by repeated iPVN 
injection of H3.  In keeping with this, a suppression of TRH release and an increase in 
SRIF release was seen from hypothalamic slices following administration of 10nM 
H3.  The sympathetic nervous system (SNS) interacts closely with the HPT axis to 
regulate both energy expenditure and thyroid gland responsiveness to TSH.  It is 
possible that suppression of TSH might be accompanied by modulation of the SNS 
both to normalize energy expenditure and normalize plasma T3 [25].  The effects of 
repeated H3 administration differ from those of other orexigenic peptides such as 
NPY, AgRP and ghrelin.  NPY, AgRP and ghrelin significantly increase food intake 
with repeated administration however, they also decrease energy expenditure thereby 
contributing to body weight gain.  
 
In conclusion, we have demonstrated that acute iPVN administration of high dose H3 
increases food intake, suppresses plasma levels of TSH but does not alter energy 
expenditure.  We have shown for the first time that repeated iPVN administration of 
H3 is effective for 7 days and increases cumulative food intake and plasma leptin, but 
does not significantly increase body weight.  Repeated iPVN H3 treatment results in a 
suppression of plasma TSH without alteration in plasma T3.  This effect is 
independent of food intake, since it also occurs in pair-fed animals.  The longer term 
effects of H3, either by virally-mediated over-expression or in transgenic animals, on 
body weight, energy expenditure and the HPT axis would be of great interest. 
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Legends 
 
Figure 1:  
Effect of acute iPVN administration of H3 (180-1620 pmol) on 1 hour food intake in 
satiated male Wistar rats in the early light phase.  * = p < 0.05 vs vehicle, n=10-12.  
 
Figure 2: 
Effect of acute iPVN administration of H3 (540 pmol) on plasma TSH at 15 and 30 
minutes post-injection.  * = p< 0.05 vs vehicle, n=9-11. 
 
Figure 3: 
A) Effect of repeated iPVN administration of vehicle or H3 (180 pmol/injection) in ad 
libitum fed rats on 24 hour food intake on day 1 and day 7, * = p < 0.05 vs vehicle, 
n=8-11. 
 
B) Effect of repeated iPVN administration of vehicle or H3 (180 pmol/injection) in ad 
libitum fed rats on 1 hour food intake in the early light phase on day 1 and day 7, * p 
< 0.05 vs vehicle, n=8-11. 
 
Figure 4:  
Cumulative food intake after repeated iPVN administration of vehicle, H3 in ad 
libitum fed rats (180 pmol/injection) or H3 in pair-fed (PF) rats for 7 days. White 
circles = vehicle; plus sign = H3 ad libitum fed group; black triangle = H3 pair fed 
group, * = p < 0.05 vs vehicle, n=8-11. 
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Figure 5: 
Effect of repeated iPVN administration of vehicle, H3 in ad libitum fed rats (180 
pmol/injection) or H3 in pair-fed ( PF) for 7 days on plasma TSH, *p< 0.05 vs 
vehicle, n=8-11. 
 
 
Table 1:  
The effect of 7-day repeated iPVN administration of vehicle or H3 (180pmol) on 
epididymal fat pad weight (WAT), BAT weight, UCP-1 mRNA expression, plasma 
leptin, plasma TSH and free T3, n=8-11. 
. 
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Figure 2 
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Figure 3A 
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Figure 4 
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Figure 5 
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Table 1:  
 
 Vehicle H3 (180 pmol) H3 PF (180 pmol) 
WAT (g) 3.35 ± 0.27 4.05 ± 0.32 3.31 ± 0.23 
Leptin (ng/ml) 2.24 ± 0.40 3.67 ±0.55 * 2.05 ± 0.49 
BAT (g) 0.54 ± 0.03 0.61 ± 0.04 0.56 ± 0.04 
UCP-1 mRNA 
(U) 
12.83 ± 1.80 14.28 ± 2.36 12.42 ± 2.65 
TSH (ng/ml) 3.93 ± 0.53 2.44 ± 0.30* 2.59 ± 0.36* 
Free T3 (pg/ml) 1.24 ± 0.14 1.53 ± 0.14 1.76 ± 0.22 
Vehicle – vehicle-treated, ad libitum fed;  H3 – H3-treated, ad libitum fed; H3 PF – 
H3-treated, pair-fed to median food intake of vehicle-treated animals. Data shown as 
mean ± SEM. * = p < 0.05 vs vehicle 
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